Cervical cancer: prevention, screening, and early detection

Jo Ann Rosenfeld

doi:10.1017/CBO9780511545672.017

17 - Cervical cancer: prevention, screening, and early detection

from Part IV - Cancer prevention

Published online by Cambridge University Press: 21 August 2009

Jo Ann Rosenfeld

Edited by

Jo Ann Rosenfeld

Show author details

Jo Ann Rosenfeld: Affiliation:
Professor Johns Hopkins School of Medicine, Baltimore, MD
Jo Ann Rosenfeld: Affiliation:
The Johns Hopkins University

Book contents

Get access

Summary

Case: S.T. is a 45-year-old mother of two grown-up daughters. She comes in, complaining of fatigue. She is sleeping well and physical examination is normal, except for a 18-week-size uterus. She has not had a Pap test for 15 years. She complains of heavy and frequent menstrual periods, but considers this normal. Laboratory tests show a hematocrit of 21, with hemoglobin of 7.3 g/dl. Pap test reveals cells consistent with carcinoma.

Incidence

The incidence of cervical cancer has decreased since the 1950s and stabilized in the 1980s in the USA. Approximately 13 000 women will develop cervical cancer yearly, and approximately 4500 will die from it. Because the incidence and mortality of cervical cancer have decreased by more than 40% since 1973 and the push for mass screenings, the Agency for Health Care Policy and Research (AHCPR) has given Pap tests an “A” recommendation, despite poor evidence for their efficacy. In many cases, cervical cancer can be prevented.

The rate of cervical cancer varies widely with race. The highest incidence in the USA is among Vietnamese women, but the highest death rate is in African-American women, being approximately 50% higher than that of Caucasian Americans. Death rates for cervical cancer increase with increasing age. Because stage I (invasive but localized) cancer has a 90% five-year survival rate, while stages III and IV (advanced invasive and/or metastatic) have a five-year survival rate of 12%, screening and early detection are possible, effective, and essential. Prevention may or may not be possible.

Keywords

cervical cancer cervical intraepithelial neoplasia human papilloma virus invasive cancer Pap test

Type: Chapter
Information: Women's Health in Mid-Life
A Primary Care Guide
, pp. 287 - 292

DOI: https://doi.org/10.1017/CBO9780511545672.017 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Greenlee, R. T., Murray, T., Bolden, S. and Wingo, P. A.Cancer statistics, 2000. CA Cancer J. Clin. 2000; 50:7–33CrossRef Google Scholar PubMed

Agency for Health Care Policy and Research. Evaluation of Cervical Cytology. Evidence report/technology assessment No. 5. Rockville, MD: Agency for Health Care Policy and Research; 1999

Ries, L. A. G., Kosary, C. L., Hankey, B. E., et al. (eds). SEER Cancer Statistics Review, 1973–1996. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 1999

Nuovo, J., Melnikow, J. and Howell, L. P.New tests for cervical cancer screening. Am. Fam. Physician 2001; 64:780–86Google Scholar PubMed

Sawaya, G. F. and Grimes, D. A.New technologies in cervical cytology screening: a word of caution. Obstet. Gynecol. 1999; 94:307–10Google Scholar PubMed

Macgregor, J., Campbell, M. K., Mann, E. M. and Swanson, K. Y.Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. Br. Med. J. 1994; 308:1407–11CrossRef Google Scholar PubMed

Limaye, A., Connor, A. J., Huang, X. and Luff, R.Comparative analysis of conventional Papanicolaou tests and a fluid-based thin-layer method. Arch. Pathol. Lab. Med. 2003; 127:200–204Google Scholar

ACOG committee opinion. New Pap test screening techniques. Number 206, August 1998. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int. J. Gynecol. Obstet. 1998; 63:312–14CrossRef

Coste, J., Cochand-Priollet, B., Cremoux, P., et al.Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. Br. Med. J. 2003; 326:733CrossRef Google Scholar PubMed

American Cancer Society. American Cancer Society issues new cervical cancer early detection guidelines. www.cancer.org/docroot/MED/content/MED_2_1x_American_Cancer_Society_Issues_New_Cervical_Cancer_Early_Detection_Guidelines.asp. Accessed March 6, 2003

Castle, P. E.Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002; 95:2145–51CrossRef Google Scholar PubMed

Hughes, S. A., Sun, D., Gibson, C., et al.Managing atypical squamous cells of undetermined significance (ASCUS): human papillomavirus testing, ASCUS subtyping, or follow-up cytology?Am. J. Obstet. Gynecol. 2002; 186:2010–16CrossRef Google Scholar PubMed

Mitchell, M. F., Schottenfeld, D., Tortolero-Luna, G., et al.Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol. 1998; 91:626–31Google Scholar

Wright, T. C. Jr, Cox, J. T., Massad, L. S., et al.2001 consensus guidelines for the management of women with cervical cytological abnormalities. J. Am. Med. Assoc. 2002; 287:2120–29CrossRef Google Scholar PubMed

Solomon, D., Schiffman, M. and Tarone, R.Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer. Inst. 2001; 93:293–9CrossRef Google Scholar PubMed

Montz, F. J., Monk, B. J., Fowler, J. M. and Nguyen, L.Natural history of the minimally abnormal Papanicolaou smear. Obstet. Gynecol. 1992; 80:385Google Scholar PubMed

Shin, C. H., Schorge, J. O., Lee, K. R. and Sheets, E. E.Cytologic and biopsy findings leading to conization in adenocarcinoma in situ of the cervix. Obstet. Gynecol. 2002; 100:271–6Google Scholar PubMed

Solomon, D., Davey, D., Kurman, R., et al.The 2001 Bethesda system. J. Am. Med. Assoc. 2002; 287:2114–19CrossRef Google Scholar PubMed

Geier, C. S., Wilson, M. and Creasman, W.Clinical evaluation of atypical glandular cells of undetermined significance. Am. J. Obstet. Gynecol. 2001; 184:64–9CrossRef Google Scholar PubMed

Schiffman, M. H. and Brinton, L. A.The epidemiology of cervical carcinogenesis. Cancer 1995; 76:1888–9013.0.CO;2-H>CrossRef Google Scholar PubMed

Parazzini, F., Vecchia, C., Negri, E., et al.Case–control study of oestrogen replacement therapy and risk of cervical cancerBr. Med. J. 1997; 315:85–8CrossRef Google Scholar PubMed

Schiffman, M. H., Bauer, H. M., Hoove, R. R. N., et al.Epidemiological evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 1993; 85:958–64CrossRef Google Scholar PubMed

Munoz, N., Bosch, F. X., Sanjose, S., et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003; 348:518–27CrossRef Google Scholar PubMed

Lombard, I., Vincent-Salomon, A., Validire, P., et al.Human papillomavirus genotype as a major determinant of the course of cervical cancer. J. Clin. Oncol. 1998; 16:2613–19CrossRef Google Scholar PubMed

Moodley, M., Moodley, J., Chetty, R. and Herrington, C. S.The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int. J. Gynecol. Cancer. 2003; 13:103–10Google Scholar PubMed

Book contents

17 - Cervical cancer: prevention, screening, and early detection

Summary

Keywords

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive